To ask the Secretary of State for Health and Social Care, what other aspects of medicines regulation including regulation related to patient safety is postponed due to contingency planning for the UK leaving the EU without a deal; and if he will make a statement.

The Government is committed to making sure that patients continue to access safe and innovative medicines and devices, and regulation related to medicines and patient safety have therefore not been postponed because of contingency planning.

For example, we have continued with the implementation of the Falsified Medicines Directive, which is designed to help identify and remove falsified medicines from the supply chain, ahead of coming into force in February 2019, and continued to make the necessary preparations to implement the new Clinical Trials Regulation and Medical Devices Regulation, both due to be implemented before the end of 2020.